[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007065128A3 - Alpha-defensine humaine inhibant la liberation de l'interleukine-1beta - Google Patents

Alpha-defensine humaine inhibant la liberation de l'interleukine-1beta Download PDF

Info

Publication number
WO2007065128A3
WO2007065128A3 PCT/US2006/061404 US2006061404W WO2007065128A3 WO 2007065128 A3 WO2007065128 A3 WO 2007065128A3 US 2006061404 W US2006061404 W US 2006061404W WO 2007065128 A3 WO2007065128 A3 WO 2007065128A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
interleukin
defensins
release
inflammation
Prior art date
Application number
PCT/US2006/061404
Other languages
English (en)
Other versions
WO2007065128A2 (fr
Inventor
Jishu Shi
Shelly Aono
Wuyuan Lu
Original Assignee
Univ Auburn
Jishu Shi
Shelly Aono
Wuyuan Lu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Auburn, Jishu Shi, Shelly Aono, Wuyuan Lu filed Critical Univ Auburn
Publication of WO2007065128A2 publication Critical patent/WO2007065128A2/fr
Publication of WO2007065128A3 publication Critical patent/WO2007065128A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les a-défensines humaines sont des inhibiteurs du traitement post transitionnel et de la libération de l'interleukine-1ß. L'interleukine-1ß est une cytokine clef intervenant dans l'amorçage et l'amplification du processus inflammatoire y compris dans l'inflammation dans des maladies telles que la maladie de Crohn et la colite ulcéreuse. On a en particulier découvert que la défensine humaine 1 de neutrophiles (HNP-1) produite principalement par les neutrophiles, et la a-défensine 5(HD-5) humaine produite par les cellules de Paneth bloquaient le traitement post transitionnel et la libération de l'interleukine-1ß. L'invention porte donc sur une préparation pharmaceutique et une méthode de traitement de l'inflammation de tissus de mammifères. Ladite préparation est un supplément thérapeutique d'un mécanisme métabolique de réduction de l'inflammation comprenant de la α-défensine humaine en quantité à efficacité thérapeutique ou l'une de ses amides esters ou sels, ainsi qu'un excipient pharmacocompatible. La méthode de traitement l'inflammation des tissus de mammifères consiste à administrer à un mammifère une quantité à efficacité thérapeutique de a-défensine humaine pour inhiber le traitement post transitionnel et la libération de l'interleukine-1ß.
PCT/US2006/061404 2005-11-30 2006-11-30 Alpha-defensine humaine inhibant la liberation de l'interleukine-1beta WO2007065128A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74099105P 2005-11-30 2005-11-30
US60/740,991 2005-11-30

Publications (2)

Publication Number Publication Date
WO2007065128A2 WO2007065128A2 (fr) 2007-06-07
WO2007065128A3 true WO2007065128A3 (fr) 2007-09-13

Family

ID=37806885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/061404 WO2007065128A2 (fr) 2005-11-30 2006-11-30 Alpha-defensine humaine inhibant la liberation de l'interleukine-1beta

Country Status (1)

Country Link
WO (1) WO2007065128A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039985A2 (fr) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO2000000214A2 (fr) * 1998-06-26 2000-01-06 N.V. Nutricia Preparations pharmaceutiques destinees a combattre ou a prevenir les infections superficielles provoquees par des micro-organismes
WO2003070176A2 (fr) * 2002-02-19 2003-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Defensines modifiees et utilisations de ces dernieres
US20040091498A1 (en) * 2002-05-31 2004-05-13 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
JP2004244378A (ja) * 2003-02-14 2004-09-02 Yakult Honsha Co Ltd 有用細菌含有飲食品又は医薬品原料用抗菌剤
WO2005013933A1 (fr) * 2003-07-31 2005-02-17 Universite De Liege Composition mucoadhesive comprenant du polyacrylate et une substance de chimio-attraction

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
WO2000000214A2 (fr) * 1998-06-26 2000-01-06 N.V. Nutricia Preparations pharmaceutiques destinees a combattre ou a prevenir les infections superficielles provoquees par des micro-organismes
WO2003070176A2 (fr) * 2002-02-19 2003-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Defensines modifiees et utilisations de ces dernieres
US20040091498A1 (en) * 2002-05-31 2004-05-13 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
JP2004244378A (ja) * 2003-02-14 2004-09-02 Yakult Honsha Co Ltd 有用細菌含有飲食品又は医薬品原料用抗菌剤
WO2005013933A1 (fr) * 2003-07-31 2005-02-17 Universite De Liege Composition mucoadhesive comprenant du polyacrylate et une substance de chimio-attraction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"New Alpha-Defensin-3 and 5 Synthetic peptides available from peptides international", 4 April 2005 (2005-04-04), XP002424353, Retrieved from the Internet <URL:http://web.archive.org/web/20050404193557/http://pepnet.com/alphadefensins.html> [retrieved on 20070313] *
BEVINS CHARLES L: "Events at the host-microbial Interface of the gastrointestinal tract - V. Paneth cell alpha-defensins in intestinal host defense", AMERICAN JOURNAL OF PHYSIOLOGY - GASTROINTESTINAL AND LIVER PHYSIOLOGY, vol. 289, no. 2, August 2005 (2005-08-01), pages G173 - G176, XP009080437, ISSN: 0193-1857 *
CUNLIFFE R N: "alpha-Defensins in the gastrointestinal tract.", MOLECULAR IMMUNOLOGY, vol. 40, no. 7, November 2003 (2003-11-01), pages 463 - 467, XP009080438, ISSN: 0161-5890 *
DATABASE WPI Derwent World Patents Index; AN 2004-629743 *
SHI JISHU ET AL: "Inhibition of interleukin-1 beta release from monocytes by human alpha-defensins", GASTROENTEROLOGY, vol. 130, no. 4, Suppl. 2, April 2006 (2006-04-01), & DIGESTIVE DISEASE WEEK MEETING/107TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; LOS ANGELES, CA, USA; MAY 19 24, 2006, pages A234, XP009080505, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
WO2007065128A2 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
Memar et al. Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections
Zhang et al. Puerarin prevents LPS-induced osteoclast formation and bone loss via inhibition of Akt activation
JP2020169220A (ja) 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法
NZ620887A (en) A novel formulation of diclofenac
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
BR0209922A (pt) Método para tratar uma condição médica que envolve a angiogênese em um paciente, para inibir a vascularização de células endoteliais, e para tratar câncer em um mamìfero
HK1101804A1 (en) Rasagiline orally disintegrating compositions
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
CA2632207C (fr) Utilisation de calcitonine pour traiter la pr
NZ599344A (en) Formulations comprising triptan compounds
CA2950385A1 (fr) Composes or (i)-phosphine utilises comme agents anti-bacteriens
WO2006115770A3 (fr) Preparations pharmaceutiques d&#39;olazanpine en comprimes a desintegration orale
CA2950384A1 (fr) Composes a base d&#39;or (i)-phosphine en tant qu&#39;agents anti-bacteriens
Leroy et al. Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling
TW200603816A (en) Risedronate compositions and their methods of use
JP2008518974A5 (fr)
CA2364451A1 (fr) Medicaments contre les affections articulaires
SI1528931T1 (sl) INHIBITORJI DIPEPTIDIL-PEPTIDAZE IV ZA ZMANJšANJE HITROSTI KRONIčNEGA PRIDOBIVANJA TELESNE TEžE
WO2006124477A3 (fr) Compositions destinees a une polytherapie et leurs methodes d&#39;utilisation
WO2007065128A3 (fr) Alpha-defensine humaine inhibant la liberation de l&#39;interleukine-1beta
MALAYERI et al. A comparison of the effects of quercetin hydrate with those of vitamin E on the levels of IL-13, PDGF, TNF-α, and INF-γ in bleomycin-induced pulmonary fibrosis in rats
EP2219650B1 (fr) Compositions et procédés permettant de traiter des troubles fibroprolifératifs
Kepka et al. Mechanisms involved in apoptosis of carp leukocytes upon in vitro and in vivo immunostimulation
JP6778200B2 (ja) Ｓｐｉｒａｎｔｈｅｓ ｓｉｎｅｎｓｉｓ抽出物を含有する組成物およびその薬学的適用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06846418

Country of ref document: EP

Kind code of ref document: A2